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A B S T R A C T
Exosomes are biological nanoparticles (30−150 nm) secreted in the extracellular area from all of cells, that
mediate intercellular message. Exosomes act as the carriers for numerous proteins, DNAs, RNAs and cell-sig-
naling molecules. Therefore, exosomes secreted by the tumor cells are useful for diagnostic purposes because of
their persistent presence in the blood and their provision of genetic cargo similar to those in tumor. Due to the
risks of aggressive activity and ambiguity of biological activity in other tissues, the use of exosomes in drug
delivery and imaging has been limited. However, their high loading, stability and longer circulation time, ex-
cellent targeting, high cell penetration performance, and optimal biodegradability have made them potential
agents in targeted cancer treatment. Therefore, in addition to examining methods for isolating and loading
exosomes, this paper discusses the applications of exosomes in biological measurement, imaging, and ther-
apeutic activities. Also, this review describes the challenges of using exosomes compared to conventional
methods and shows that it is very useful to use them due to less aggressive activities. Finally, this review
attempts to provide an appropriate incentive by showing the performance of exosomes in cancer therapy through
targeted drug delivery, gene therapy, imaging and diagnosis.
1. Introduction
Nanotechnology has provided new insights for the early detection
and cancers therapy based on nanocarriers such as extracellular vesicles
and organic or non-organic mesoporous nano membranes. Since ex-
tracellular vesicles provide strong potential for application in ther-
apeutic interventions, with a safe and accurate treatment method
compared to other nanoparticles, they have been highly regarded as
potential drug carriers in recent studies. Extracellular vesicles are
mainly composed of cell membranes derived from cell destruction, and
they can act as chemical messengers based on the proteins and RNAs
being carried to establish communications between cells [1]. They are
categorized into three groups according to the origin, synthesis and the
size of the particles, namely, (1) exosomes (30−150 nm), (2) ectosomes
(50nm-1 μm), and (3) apoptotic bodies (50nm-5 μm) [2–4]. Exosomes
may be extracted via various extracellular fluids, such as urine, blood,
and cerebrospinal fluid. They were first identified by Trams, et al. [5]
and then examined by Johnstone, et al. [6]. Protein or peptide com-
pounds within the exosomes can indicate the presence of cancers types,
inflammation, viral infections, and neurodegenerative problems [7].
However, based on the cellular source, the exosomes encompass many
proteins and lipids. Because, the results illustrate that the exosomes are
used by the cells as the main pathway for removing unused or harmful
proteins, if there are no lysosomal degradation systems [8]. The most
public proteins in exosomes contain fusion proteins, heat shock pro-
teins, membrane proteins (monoclines, Rab GTPases, flotine), multi-
vesicular bodies proteins (TSG101, alixes, proteins) and tetraspanins
[9], while the most common lipids include sphingolipids, cholesterols,
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and ceramides [10]. Also, one of the inherent powers of the exosomes is
the development of cancer in other parts through the collaboration of
the receptor-ligand at the cells and the transmission of metastatic
messages into the cells [11,12]. Therefore, based on the mechanism
above, exosomes can transfer the drug to cancerous tissues and other
cells [13]. Recently, researchers have payed strong consideration in
transferring pharmaceutical compounds to exosomes for potential ap-
plication as drug carriers [8,14–16] for targeted therapies. This is be-
cause of the large loading space resulting from two-layer membrane,
suitable size, high biocompatibility and biodegradability, excellent
targeting, good modification, sustainability and simple transfer of bio-
logical barriers, as well as non-toxicity of exosomes.
In this literature, we present an outline of exosome based delivery
systems for anticancer compounds in targeted tumor therapy. We dis-
cuss the formation, structure, natural functions and appropriate sources
of exosomes for the treatment of cancers. We also discuss the me-
chanisms of loading the therapeutic compounds and modification of
exosome surfaces to increase the targeting. Finally, we review the re-
cent advances in the nano-complexes produced from exosomes and
drug compounds, and the results of their therapeutic applications. The
overall benefits and challenges of using exosomes and its promising
pathways in medical development have also been discussed.
1.1. Facts
• Exosomes are carriers with a diameter of 30−150 nm, made by a
two-layer membrane. Since these carriers are secreted by different
cells, therefore, based on the intrinsic nature, the exosomes struc-
ture, their function and distribution are highly variable.
• The presence of various proteins in exosomes can lead to various
activities with positive or negative effects, which ultimately cause
problems in their homogeneous production as well as difficulties in
their clinical activity.
• The proteins present in the Golgi system, endoplasmic reticulum,
mitochondria or nucleus of cells in exosomes are not observed.
Therefore, it can be considered that exosomes are one of the path-
ways for eliminating undegraded endosomal or lysosomal proteins.
1.2. Opening question
• What are the most common methods for synthesizing tumor-derived
exosomes, purification, surface modification and their effects on
cancer treatment activities despite metastatic activities?
• Based on the unique status of the exosomes due to protein differ-
ences, size, etc., how can the therapeutic activities of the exosomes
be controlled and improved?
• Based on the results, the anti-tumor activity of the exosomes gen-
erally returns to the detection and transmission of anti-tumor
compounds. While, the direct effect of exosomes on tumor activity is
confusing. Based on the origin of the produced exosomes, is the use
of exosomes in treating cancer cells can have negative effects on
non-target cells and even induced disease development?
2. Structure and biogenesis of the exosomes
As determined, exosomes with dimension 30−150 nm are a two-
layer membrane with compounds such as proteins, fats, and sometimes
organelles of the original cells, which are formed by most cells in
mammals for intercellular communication (Fig. 1A). Since the synthesis
of an exosomes from a cell is done randomly or intuitively from a cell's
part, they are faced with high heterogeneity even when they are pro-
duced from a type of cell or tissue [17]. In the same vein, cancer cells
use exosomes for intercellular communication, which called to as me-
tastasis. Therefore, exosomes can be considered as profiles for detecting
and even treating cancers [18]. For this activity, it is necessary to
provide accurate definitions of biography, physiological function, and
empirical events of exosomes. Hence, by providing definitions of bio-
genesis, the above strategy can be achieved as much as possible. Despite
the identification of the two ways for the development of exosomes, the
mechanism of the biogenesis of exosomes is still unknown. In the fol-
lowing sections we will overview the exosomes biogenesis and related
pathways.
2.1. Endosomal assorting collections necessary for shipping (EACNS)
mediated corridor
The initial phase in the formation of exosomes is the creation of
intraluminal vesicles (ILVs). Despite the presence of various complexes
in the ILVs production, the most important is the EACNS that consisting
of two dozen protein with 5 collections [19]. Briefly, the procedure for
the synthesis of exosome begins with the EACNS-0 through interaction
with the phosphatidylinositol 3-phosphate and connects to the ubiqui-
tinated vehicle through Zinc Finger Domains and Ubiquitin-interacting
Motifs, respectively [20]. Then, an amplitude in the C-terminus of the
Hrs subunit of EACNS-0 led to EACNS-I. In fact, EACNS-I with EACNS-II
is a complex that induces endosomal budding from the cytoplasm.
During the germinating, EACNS-0 cargo is transmitted to them. After
the formation of buds, the well-ordered multivesicular body protein 6
of the EACNS-III assembled nonstop attaches to EACNS-II. This protein
acts as a ring around the bud's neck for isolating buds [20].
2.2. EACNS-independent corridor
Along with the formation of ILV, there is an independent corridor to
EACNS based on lipids like a ceramides that may play a role in the
formation of exosomes [21]. However, the second route is still unclear
and could be with multiple sorting and regeneration apparatuses that
are independent of the membrane germination.
2.3. Aspects inducing the biogenesis of exosomes
Despite the influence of exosome production techniques on the
performance of exosomes, biological factors such cell type, cellular
communication, etc. are also highly effective in the production of exo-
somes. For instance, undeveloped dendritic cells generate a restricted
number of exosomes [22] compared with mesenchymal stem cells
(MSCs) [23]. Also, shutdown of cells by blocking cellular communica-
tions reduces the production of exosomes. In this regard, the results of
Kucharzewska, et al. [24], Savina, et al. [25], and Koumangoye, et al.
[26] showed that the use of hypoxia, Ca2+ ionophors and cell detach-
ment compounds increases the secretion of the exosomes, respectively.
Therefore, it is required to pay consideration to the environment sur-
rounding the cells, the type of cell, and the stimulant or inhibitor
compounds in the production of exosomes as well as the methods used.
2.4. Appropriate source cells for engineered exosomes
Despite the widespread use of cell types in the production of exo-
somes, due to the different biological functions of the exosomes caused
by various compounds of proteins, fats, and even different surface
biomarkers in the exosomes (Fig. 1B), it does not seem possible to use
any cells types. Therefore, determining the advantages and dis-
advantages of the cells used in the production of exosomes is the one of
the main priorities. For example, exosomes from tumor cells simply
carry cancer cell antigens that can form metastasis processes [27],
while it is shown that the exosomes derived from cancerous cells in a
tumor detection and targeted drug delivery are very appropriate [17].
In this field, Harris, et al. [28] showed that the proteases like a ur-
okinase plasminogen activator and cathepsin D in exosomes stimulate
the metastasis of breast cancerous tumors. Also, the lack of uniformity
in the production of exosomes from cancerous tumors and their com-
plex separation from tumors due to invasive sampling has made it
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difficult to develop this kind of exosomes [29]. Likewise, the use of
immature dendritic cells is best option for the generating exosomes
from human or animal resources due to less immune response of pro-
duced exosomes with the lowest of surface biomarkers like a MHC-I,
MHC-II, CD40, and CD86 on their surface [23,30]. Nonetheless, as
summerized in Table 1, the exosomes resulting from undeveloped
dendritic cells are sometimes effective in the development and growth
of cancer cells. Therefore, based on the information above, it seems that
application of the exosomes derived from plant cells and then healthy
mammalian cells, is much safer than tumor cells for clinical activity. In
Fig. 1. (A) Biogenesis of exosomes, (B) Main classes of compounds contained in the exosome (C) Various techniques used for isolation: (a) Ultracentrifugation, (b)
Precipitation, (c) Immunological (d) Filtration, (e) Microfluidic-based, and (D) characterization and analysis of exosomes: (a) TEM, (b) DLS, (c) Bradford assay (d)
Flow cytometry, (e) Western blot.
Y. Zheng, et al. Biomedicine & Pharmacotherapy 129 (2020) 110442
3
Table 1
The function of MSCs-derived exosomes.
Source of exosomes Performance Ref.
Human bone marrow-derived MSCs Enhanced breast tumor growth in vivo [109]
Multiple myeloma-derived MSCs multiple myeloma cell growth in vitro, Tumor growth in vivo [110]
Glioma Associated-human MSC Rise the tumorigenicity of glioma stem-like cells [111]
Fig. 2. Oral administration of grape exosome-like nanoparticles (GELNs) attenuates the severity of colitis induced by dextran sulfate sodium (DSS). Lgr5-EGFP-IRES-
CreERT2 mice were treated for 7 days with 2mg/mouse of GELNs in 200 μl PBS: (a) GELN-treated mice presented with a better body condition after 7-day of
treatment. (b) Survival analysis. Intestinal morphometry of (c) intestinal length and (d) villus height. (e) EGFP+ and Ki67+ cells in frozen sections of intestine were
examined by confocal microscopy and quantified (right, n=5). The arrowhead indicates EGFP+Ki67+ cells. (f) Real-time analysis of mRNA expression of different
genes in the intestinal crypts from C57BL/6 j mice. (g) Confocal analysis of nuclear translocation of β-catenin (top panels) and phosphorylation of GSK-3β (Ser 9)
(bottom panels) in the crypt sections from DSS-treated C57BL/6 j mice [32]. Figures adopted and modified from refs [32] with permission from the American Society
of Gene Therapy.
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this regard, fruit- or food-derived exosomes due to their current con-
sumption and cheapness have attracted much attention [31]. In a mice
model, Ju, et al. [32] using grape exosome-like nanoparticles was able
to increasing the maintenance, growth, and differentiation of intestinal
SCs against colitis caused by dextran sulfate sodium (Fig. 2). Likewise,
it was found that by modifying the exosomes surface derived from
grapefruit and loading doxorubicin and curcumin drugs into them, in
addition to improving targeted drug delivery, inflammatory activities of
tumors in mice was significantly reduced [33].
3. Loading, isolation and surface modification of exosomes
3.1. Exosomes isolation
Access to exosomes due to their presence in the blood, milk, urine,
saliva and other physiological fluids is simply possible. However, their
isolation is always challenging, difficult, complex, and costly. The most
important separation methods are ultracentrifugation, immuno-affinity,
precipitation, and so on, each with advantages and disadvantages as
reported in Table 2 (Fig. 1C). Based on the type of physiological fluid,
the isolation of the exosomes is different, despite the common princi-
ples based on size, and biophysical characterization like an immuno-
affinity [21,34]. After separation, the purity and characterization of the
exosomes are then evaluated and quantified through common methods
such as imaging, western blotting and flow cytometry (Fig. 1D).
3.2. Loading mechanisms
Although there are various strategies for loading drug compounds
into exosomes, they may be separated into two passive and active
loading categories (Table 3). Loading of drug compounds in exosomes
has major challenges, most notably the control of membrane integrity,
and the presence of bioactive compounds within the exosomes, which
can greatly reduce the efficiency of the transfer. To this purpose, if the
membrane integrity remains, the offloading of the exosomes content
will be a good solution, while, some detail information is not available
in this field. In this regard, plant-derived exosomes have been shown to
have more bioactive compounds than animal-exosomes [35].
The common method of loading drug compounds on exosomes is
incubation before (loading the drug in the cells of the exosomes source)
and after their production, which has the least destructive effects on
both of them [36]. While, some of studies suggest that the best way to
load membrane-impermeable drugs, mi- or si-RNAs, and small DNA is
via electroporation, which can cause pores on the membrane of two
layers of exosomes to be loaded and cover the exosome [37].
3.3. Surface modification
Exosomes, like other particles, are absorbed and removed by the
reticuloendothelial system after being secreted or injected into the
bloodstream [38]. Besides, studies have exposed that exosomes act to
transmit cellular signals or drug compounds loaded into them through a
three-pitch receptor interplay, membrane fusion, and endocytosis me-
chanism [38,39]. Therefore, in order to more accurate detecting the
target tissue or cells, increasing the stability of exosomes in body, and
induction of intracellular penetration, comprehensive information must
be provided from surface receptors and surface modification of exo-
somes. Differences in biological activity of exosomes, in addition to
Table 2
The advantages and disadvantages of the exosome isolation techniques.
Methods Mechanism Advantage Disadvantage
Ultracentrifugation Based on centrifugal
force
High purity, Isolation of low-density exosomes and
high density, Isolation of very few samples, Suitable
for protein analysis, Long lifespan.
Poor recovery of exosomes from highly viscous biofluids, Time
consuming, Expensive, Multiple-steps, Change morphology.
Immunological isolation Based on antibody
receptor interaction
Rapid, Relatively simple, Can be tissue specific, High
purity, No volume limitations.
Some of exosomes may not preserve biological functionality,
Expensive, Not suited for large sample, Need expensive laboratory
equipment, only cell-free sample used.
Filtration Based on membrane
materials and porosity
Preserves vesicle structure, Fast, Easy, Non-specific
binding of vesicles, Scalable, Separation with high
density.
Low purity (Contamination with other microvesicles), Low
efficacy, Necessities extra steps such as ultracentrifugation,
Isolation based on size only.
Precipitation Based on polymer
materials and
precipitation
Rapid, Appropriate with cheap tools, Capability to
detect biomarkers, Large samples can be used.
High heterogeneity, Not specific for exosomes, High impurity.
Chromatography Based on porosity of
materials
High efficacy, Determination of surface phenotype,
Scalable, Can be tissue specific, High recovery.
Nonspecific bindings, Expensive, Need to high focus, Variable level
of impurities, Chromatography column contamination, Time-
consuming protocols.
Microfluidics‐based Based on microfluidic Quick, Easy, Work with small sample, High
sensitivity.
Needs to developed laboratories, Expensive, Contamination with
microvesicles, Not matched with large samples, Lack of global
protocol.
Table 3
Methods of loading drug compounds in exosomes.
Classification Sub-classification Advantages Disadvantage
Passive Incubation of exosomes or donor cells
with compound drugs
Easy, Has membrane integrity, Good stability, Lack of
morphology change, Do not need extra tools.
Low loading efficacy, Cytotoxicity to the donor cells.
Active Sonicating High loading efficacy, Applicable for small RNAs,
Rapid.
Low membrane integrity, Not efficient for hydrophobic drugs,
Morphology change, Mechanical stress.
Extrusion High loading efficacy, Time conserving. Low membrane integrity, Morphology change.
Electroporation Loading large molecules such as siRNA, Low loading efficiency for hydrophobic molecules,
Agglomeration. Morphology change, Mechanical stress,
Antibody binding Specific Multi-step activities
Saponin-assisted Enhanced drug loading Toxicity, Hemolysis, Lack of integrity, Presence of saponin in
products.
Click chemistry Fast, Medium efficiency. –
Freezing Medium loading Agglomeration.
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Fig. 3. (A): (a) Effect of AA-PEG-DSPE incorporation and paclitaxel (PTX) loading on fluidity of exosomal membranes, (b) 3LL-M27 cells were incubated with
fluorescently-labeled AA-PEG-exo, or PEG-exo, or exo for various times, and accumulation levels were measured, (c) AA-PEG-exo formulation showed a dose-
dependent response to competitive inhibition by AA, indicating that this formulation entered cells by receptor mediated endocytosis, (d) C57BL/6 mice with
established Luc/mCherry-3LL-M27 lung metastases were i.v. treated with: saline, or Taxol, or exoPTX, or AA-PEG-exoPTX, or exosomes alone (no drug), (e)
Quantitative assessment of metastases area on the lung slides of animals treated with: 1) saline, or 2) Taxol, or 3) exoPTX, or 4) AA-PEG-exoPTX, or 5) exosomes
alone and (f) A survival of C57BL/6 mice with established metastases was recorded for four treatment groups: 1) saline (dimonds), or Taxol (squares), or 3) exoPTX
(triangles), or 4) AA-PEG-exoPTX (crosses), or 5) exosomes alone (stars) [58]. (B): (a) Characteristics of A33Ab-US-Exo/Dox, (b) Confocal microscopy images of
LIM1215 cells after incubation with Dox, A33-Exo/Dox, and A33Ab-US-Exo/Dox for 4 h, (c) Viability of LIM1215 cells was detected by CCK-8 assay after treated with
A33Ab-US-Exo for 24 h, (d) Cell apoptosis and necrosis of LIM1215 cells treated with DOX, A33-Exo/Dox, and A33Ab-US-Exo/Dox for 24 h and measured by flow
cytometry using annexinV-APC kit and PI staining, (e) in vivo fluorescence signals of mice bearing LIM1215 cell-derived tumors after intravenous injection of DiR,
A33-Exo/DiR, and A33Ab-US-Exo/DiR and (f) Tumor volume of tumor-bearing mice treated with groups [59]. Figures adopted and modified from refs [58] and [59]
with permission from Nanomedicine: Nanotechnology, Biology and Medicine, respectively.
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cellular source, return to their surface molecules [40]. So, surface
modification of the exosomes by cellular engineering or chemical
modification is widely used to improve pharmacokinetic behavior [41].
Since exosomes intrinsically absorb some of the protein, fat, and other
ligands from the original cells, it is based on the hypothesis that exo-
somes with known surface markers can be provided by injection of
encoded genes into the original cell. For this purpose, using a vector of
gene transfer like a lentiviral, fusion cassette is stated in parental cells
and then transmitted to exosomes. For instance, recently Limoni, et al.
[42] were able to track the breast tumor cells and inject drug com-
pounds by applying exosomes modified with HER2 that constructed via
encoding the LAMP2b-DARP in G3 chimeric gene in HEK293 T cells.
Besides, chemical modification in the exosomes is considered as a
method of quick, simple, efficient, and the presentation of one or more
specific site to make changes [41]. Despite the introduction of different
methods, procedures that prevent from the destruction and accumula-
tion of exosomes membranes during temperature and pressure changes
should be used. Based on this method, it is possible to loading a variety
of small and large molecules, target molecules, imaging molecules, etc.
on the exosomes by various chemical groups such as alkyne, carboxyl,
and so on [43]. In this field, Tian, et al. [44] using a group of alkyne in
bio-orthogonal copper-free azide, were able to produce modified exo-
somes with c(RGDyK) peptide containing the curcumin for the treat-
ment of cerebral ischemia.
4. Exosomes as a therapeutic application
Because organic and non-organic nanoparticles used for therapeutic
application especially drug delivery and detection are faced with dif-
ferent cytotoxicity, non-targeting and immunogenicity [45], the using
exosomes in the transfer of therapy compounds such as drug, imaging
labels, etc. is an ideal solution for crossing biological barriers, reducing
cytotoxicity and immunogenicity activities [46,47]. Furthermore, their
two-layer membranes are a natural protector and an ideal capsule for
drug release. Also, in resistant drug-resistant cancerous cells, the use of
exosomes from a cancer cells and loading drugs or other compounds on
their surface could be a great way to control growth and stop cancer
cells [15]. In this regard, in a mice model, Munagala, et al. [48] by
applying the space of exosomes and its advantages in drug loading,
were able to provide potential remedial affects by transferring the drug
to lung tumor cells. Likewise, Morishita, et al. [49] using exosomes
derived from B16BL6 murine melanoma cells, were able to provide
specific responses in tumor. It was also previously determined that the
toxic concentrations of doxorubicin and its negative effect on the heart
were significantly reduced when exosomes were used for drug delivery,
in addition to suppressing the growth of breast cancer tumors [50].
However, in order to obtain the promising therapeutic effect on tumors,
in addition to choosing the potential loading method and generating the
exosome, there must be an appropriate correlation between the carrier,
type of exosomes and cancer suppressor compounds such as small
molecules, nucleic acids, RNA and proteins [51]. It seems that the ap-
propriate and desirable relationship between exosomes, drug com-
pounds, and tumor type can greatly reduce the major problems of the
use of exosomes in therapeutic activities such as drug loading, the kind
of cargo, therapeutic loading and the type of surface charge.
4.1. Exosomes as a drug delivery
4.1.1. Exosomes as drug delivery vehicles for small molecules
Various studies have shown that the use of exosomes for the de-
livery of small molecules is an appropriate process. In this field,
Dhillon, et al. [52] and Sun, et al. [53] were able to transfer the cur-
cumin composition to a much higher efficiency to the target tissue.
Also, in the mice model, Sun, et al. [53] using curcumin loaded on the
exosome, in addition to the targeting of curcumin, they were able to
induce reduced lung inflammation and higher survival of the mice
compared to the only curcumin. In the same way, it was determined in
the mice model that paclitaxel loaded onto exosomes not only increased
the transfer of drug to the lung tumor tissue and increased cytotoxicity
by up to 50 times the control, but also severely reduced drug toxicity in
other tissues [54]. Furthermore, in mice model with cancer drug re-
sistance Srivastava, et al. [55] by loading gold nanoparticles containing
doxorubicin in exosomes, in addition to targeted drug delivery to lung
tumor cells, were able to increase cellular uptake of the doxorubicin
and also to carry out synchronous medical activities by gold nano-
particles. At the same time, in a mice model it was found that exosomes
containing doxorubicin in comparison with the free drug decreased
drug resistance in ovarian and breast cancer cells, reducing drug cy-
totoxicity in the heart, and increasing drug concentration in cancer
tissue [50]. Likewise, it was determined that loading paclitaxel and
curcumin in the exosomes, in addition to improving the targeted
transfer of them to the lung tumors, increase the drug's sustainability in
the blood due to the increased hydrophilicity [56,57]. In the following,
Kim, et al. [58] showed that the use of paclitaxel-containing exosomes
with amino-ethyl-anisamide-polyethylene glycol to bind to sigma re-
ceptors increases the drug's uptake and the penetration depth of the
drug to the lung tumor (Fig. 3A). In an animal model, it was also de-
termined that exosomes resulting from LIM1215 cells containing dox-
orubicin functionalized with superparamagnetic iron oxide nano-
particles and A33 antibodies, in addition to reducing drug cytotoxicity
in the heart, increased drug loading in colon cancer cells along with
simultaneous therapeutic activities such imaging or photodynamic
therapy (Fig. 3B) [59]. Moreover, Li, et al. [60] with Sorafenib loaded
on siGRP78-modified exosomes that are isolated from bone-marrow-
derived MSCs, were able to prevent the development of cancer cells and
metastatic activities, in addition to enhancing drug loading in drug
resistant hepatocellular carcinoma. Recently, Das, et al. [61] in a MDA-
MB-231 and MCF-7 cellular model, exhibited that the using exosomes
isolated from embryonic SCs containing doxorubicin not only increased
the breast cancer cells death with low dose of drug, but also improved
the performance of the drug more than the free drug. Likewise, Melzer,
et al. [62] by using exosomes resulted from human MSCs-like cell
containing Taxol, in addition to increasing the cell death of lung cancer
(A549), ovarian cancer (SK-OV-3), and breast cancer cells (MDA-hyb1),
reduced their metastatic activity up to 50 % in the lung, spleen, liver,
and kidney tissues, and a decrease of Taxol concentration up to 7.5-fold
of free drug. Overall, the results of the studies exhibit that the use of
exosome as a vehicle of small molecules reduces the cancer cells drug
resistance, reduces the toxicity of the drug in other non-target tissues,
increases the efficacy of stopping the development of cancerous cells,
and even prevents metastases.
4.1.2. Exosomes as drug delivery vehicles for peptides and proteins
Exosomes, like organic and non-organic nanoparticles, are used to
transport large molecules like a protein. For example, various studies
displayed that exosomes loaded with catalase and superoxide dismutase
enzymes [63], various antigens and nanobodies [64], proteasomes
[65], transferrin and lactoferrin [66] for targeted therapy were in-
vestigated.
Although drug treatment for progressive pancreatic cancer has been
challenged, Aspe, et al. [67] by using exosomes collected from a cell
line of melanoma containing the Survivin-T34A protein, in addition to
increasing the apoptotic activity of cancerous cells, increases the sus-
ceptibility of cancerous cells to Gemcitabine. In this regard, it was de-
termined that HEK293 T cells-exosomes derived modified with a frag-
ment of Interleukin 3 containing Imatinib protein reduced the activity
of chronic myelogenous leukemia by inhibiting tyrosine kinases
(Fig. 4A) [68]. Furthermore, a study by Koh, et al. [69] found that the
use of HEK293 T cells-exosomes derived containing a signal controlling
protein α (SIRPα) by blocking the CD47 receptor on Raji human B cell
lymphoma, HT29 human colon adenocarcinoma, and CT26.CL25
mouse colon carcinoma caused tumor stoppage in mouse model and cell
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death in cellular models through binding macrophage and T cells to
cancerous cells. Accumulation of CD47 on cancerous cells keeps them
from macrophage immune activities. Similarly, Cho, et al. [70] revealed
that exosomes isolated from a HEK293 T cells containing a SIRPα along
with protein-scaffold-based ferritin nanocage, by blocking CD47 re-
ceptors on the tumor cell, inhibited HT29 human colon
adenocarcinoma cells growth, and increased immune function
(Fig. 4B).
4.1.3. Exosomes as drug delivery vehicles for nucleic acids
Exosomes can easily transfer nucleic acids like a DNA or RNA to
targeted cells, compared with other carriers, and can cause genetic
Fig. 4. (A): (a) Exosome particles were visualized by Atomic Force Microscopy (large square 2 μm, small square 500 nm), (b) Analysis at confocal microscopy of
LAMA84 (upper panel) or K562R (lower panel) cells treated, for 3 h and 6 h, with 10 μg/mL of HEK293T-derived exosomes (Exo) and IL3L-HEK293T-derived
exosomes (IL3L Exo). Nuclei were stained with Hoechst (blue); exosomes were labeled with PKH26 (red), (c) Comparison of the median tumor volume was an index
of the antitumor efficacy of Imatinib loaded exosomes, (d) in vivo effects of Imatinib loaded IL3L-exosomes, (e) Exosome size distribution was determined by DLS
analysis [68]. (B): (a) The ratio of protein concentration (g) for Exo-SIRPα, monomeric SIRPα, and FN-SIRPα corresponding to an equal amount of SIRPα, (b) The
ability of FN-SIRPα and Exo-SIRPα to bind CD47-expressing HT29 cells, assessed by flow cytometry, (c) Analysis of HT29 cell phagocytosis by BMDMs in the presence
of a high concentration of FN-SIRPα, (d) Antitumor effect of Exo-SIRPα in HT29 tumor-bearing BALB/c immuno-deficient mice, (e) Weights of excised tumors at
experimental endpoints for HT29 mouse models [70]. Figures adopted and modified from refs [68] and [70] with permission from Theranostics and Journal of
Controlled Release, respectively.
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changes in pathogenic cells and even healthy cells [71]. Exosomes can
then be used to alter gene expression in gene therapy activities. Despite
the high instability of nucleic acids like siRNA, miRNA, etc. [72], this
compounds are used to destroy various genes. Although exosomes are
capable of improving nucleic acids stability in the blood, further re-
search and understanding is needed to incorporate nucleic acids into
exosomes and utilize of the exosomes-nucleic acids complex in genetic
therapy. In this field, Song, et al. [73] by immobilizing miRNA-7-5p in
exosomes increased the autophagy activity in human bronchial epi-
thelial cancer cells by inducing EGFR/Akt/mTOR signaling path for the
treating lung cancer. At the same time, it was found that miRNA-302b
in the exosomes of derived tumor from the lung tumor caused the
suppression of creation, movement, and attack of lung cancerous cells
by controlling the TGFβRII/extracellular signal-regulated kinase path
[74]. Also, in cellular and mice models, Bellavia, et al. [68] using BCR-
ABL siRNA loaded on exosomes modified with a fragment of Interleukin
3 that is overexpressed in chronic myeloid leukemia not only accu-
mulated siRNA in cancerous cells based on targeting delivery and re-
ducing the barrier to cancer drug resistance, but also they significantly
decreased the activity of cancer cells compared to conventional
methods. At the same time, by using exosomes isolated from normal
fibroblast cells containing siRNA or shRNA special of oncogenic
KRASG12D by blocking the CD47 receptor on the cancerous cells sur-
face, Kamerkar, et al. [75] were able to suppress advanced pancreatic
cancer. Another study determined that exosomes isolated from MSCs
containing locked nucleic acid-modified anti-miR-142-3p in cellular
4T1 and animal models decrease tumorigenicity of breast cancer cells
compared to common methods (Fig. 5A) [76]. Recently, in a cellular
model, Bai, et al. [77] revealed that the siRNA loaded with highly
targeted tLyp-1 exosomes derived from Escherichia coli with a dimen-
sion of 100 nm could easily suppress lung tumor A549 cells via
knocking-down SOX2 gene. It was also found that microRNA-145
loaded on exosomes isolated from pancreatic cancer cells via pre-
cipitation method, in addition to decreasing cell drug resistance, ef-
fectively suppresses tumorigenesis activities including proliferation,
migration, and invasion [78,79].
4.2. Exosomes as delivery of imaging molecules
One of the major problems with the imaging of tumor tissues is the
lack of complete accumulation of cancer cells in one area, which causes
strategic errors in the diagnosis and surgical treatment of tumors [80].
Since the exosomes provide the ability to detect cancerous cells at ex-
tremely high levels, even up to a few hundred cells, their application in
cancerous imaging, especially lung cancers, was considered. This means
that by attaching an optical reporter in the nanoscale dimension to the
exosomes, in addition to optical imaging, in comparison with fluores-
cence dyes, it provides a higher optical stability for imaging. In this
field, Zong, et al. [81] and Jiang, et al. [82] gained a high-resolution
image of the live cells and the metastatic activity of breast tumor cells
with minimal cytotoxicity by loading silicon quantum dots (30 nm) and
gold-carbon quantum dots onto the outer membrane of the exosome
(50−100 nm), respectively. Likewise, Srivastava, et al. [55] with the
use of iron oxide nanoparticles (5−10 nm) and doxorubicin in exo-
somes derived from Lung fibroblast cells, in a dual activity, in addition
to treatment activity in lung cancers cells (H1299 and A549), were able
to capture a high-resolution tumor. Besides, In addition, using a dioc-
tadecyl-tetramethylindodicarbocyanine-4-chlorobenzenesulfonate salt
label on exosomes extracted from CaL62/Rluc cells, Gangadaran, et al.
[83] in addition to providing a tissue and tumor edges imaging system
for reducing surgical errors of thyroid cancer, were able to visualize the
development of tumor in the body (Fig. 5B). Recently, in a mice model,
Shi, et al. [84] using exosomes modified with fluorescence radiolabeled
and PEG, were capable to imaging higher resolution from 4T1 breast
cancer cells along with providing a visual examination of cellular up-
take.
4.3. Exosomes as cancer diagnostic biomarkers
Based on the origin of the exosomes, it is possible to evaluate the
cancerous cells by detecting them in physiological fluids [85]. In other
words, exosomes as biomarkers of tumor types can be detected by na-
nobiosensors and other diagnostic methods. Based on this hypothesis,
exosomes can be exploited to monitor and even predict a patient's re-
sponse to a given treatment [86]. So, the use of exosomes in the diag-
nosis and control of remedial activities is recommended as a very suc-
cessful and safe strategy. On the other hand, due to differences in the
pattern of sampling compared to conventional methods, invasive ac-
tivity causing tumor metastatic activity will not be observed. Moreover,
a reasonable number of exosomes (at least 109 per ml) with the cancer
cell origin compared to cancerous cell proteins that are very diluted in
the early stages of cancer will allow more accurate and faster detection
of cancers in the early stages [87].
4.3.1. Exosomal proteins as biomarker
As mentioned, exosomes contain a variety of proteins, such as the
annexin, flotillin, Hsp70, Hsp90, CD9, CD37, CD53, CD63, Alix,
Tsg101, EpCam, etc., which reflect parental cells. These proteins can be
identified as cancer biomarkers by immunoassay, western blot analysis,
and so on (Table 4). In this line, Zhao, et al. [88] using microfluidic chip
based on using immunomagnetic beads with detection of CA-125,
EpCAM, CD24 exosomal proteins, were able to sense ovarian cancer at
an early period with similar accuracy to the standard Bradford method
(area under the curve (a.u.c.) = 1.0, p= 0.001 vs. a.u.c. = 1.0,
p= 0.0009) (Fig. 6B). Likewise, in a human model, Sandfeld-Paulsen,
et al. [89] showed that exosome proteins were not equally capable of
detecting lung cancer, and that the strongest ones were CD151
(a.u.c. = 0.68, p=0.0002), CD171 (a.u.c.= 0.60, p= 0.0002), and
tetraspanin 8 (a.u.c. = 0.60, p=0.0002). Nevertheless, in the multi-
biomarker model (only covered 10 biomarkers), they increased the
ability to detect all of lung cancer kinds several times (all cancer:
a.u.c. = 0.74 [95 % confidence interval: 0.70−0.80]; adenocarcinoma
only: a.u.c. = 0.76 [95 % confidence interval: 0.70−0.83]). In addi-
tion, the use of exosomes-derived from pancreatic ductal adenocarci-
noma with glypican-1 and CD63 biomarkers not only improved the rate
of cancer detection to under 30min, but also increased the detection
limit of cancer with a sensitivity of 99 % to over 82 % compared to
conventional methods (Fig. 6A) [90]. Recently, based on the diagnosis
of exosomal protein CD82, Wang, et al. [91] were able to detect breast
cancer at all stages of cancer development and in different tissues. Their
results exhibited that exosomal protein CD82 is extremely low in
healthy tissues and initial tumor and highly high in malignant and
metastatic cancers.
4.3.2. Exosomal nucleic acids as biomarker
Numerous studies have shown that nucleic acids of RNA and single-
stranded or double-stranded DNA, like a protein, are an integral part of
exosomes, the most important of which are: microRNAs (miRNAs),
messenger RNAs (mRNAs), handover RNAs (tRNAs), and long non-
coding RNAs (lnc RNAs) [92–94]. Among them, exosomal miRNAs have
taken the most consideration due to their stability against degradation
[95]. Hence, after year 2007, various studies have been done to eval-
uate them as markers of cancer cells (Table 4). In this regard, Tanaka,
et al. [96] found in a human model that miRNAs-21 is one of the ap-
propriate markers to determine esophageal squamous cell cancer
(Fig. 6D). They demonstrated that with the growth and development of
the tumor along with aggressive activities, the level of miRNAs-21 in-
creased significantly. Likewise, in a cellular model, it was found that
using great segments of double stranded genomic DNA (>10 kb), in
addition to diagnosing pancreatic cancer with high sensitivity, were
able to predict the therapeutic resistance and type of cancer treatment
based on the mutations in KRAS and p53 [97]. In addition, Jin, et al.
[98] were capable to detect high-precision adenocarcinoma and
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squamous cell carcinoma (SCC) without invasive activity using exo-
somes containing miR-181-5p, miR-30a-3p, miR-30e-3p, and miR-361-
5p for adenocarcinoma-specific; and miR-10b-5p, miR-15b-5p, and
miR-320b for SCC-specific. They also showed that in a multi-miRNAs
model the diagnosis of adenocarcinoma (AUC value of 0.936) and SCC
(AUC value of 0.911) was more accurate [98]. Furthermore, the results
of Xu, et al. [99] displayed that the simultaneous use of
ENSG00000258332.1, LINC00635 and AFP exosomal as a lnc RNAs is a
Fig. 5. (A): (a) Transmission electron micrograph of negatively stained exosomes with a diameter of 30–150 nm, labeled for CD63, (b) Cellular uptake of PKH67-
labeled MSCs-Exo by 4T1 cell lines, (c) Evaluation of the cytotoxicity effect of exosome-based LNA-anti-miR-142-3p delivery on 4T1 cells, (d) Representative dot plots
of 4T1 cancer cells, (e) Representative images of female BALB/c mice bearing 4T1 breast tumor and excised tumor tissues at the end of day 36 [76]. (B): (a)
Examination of EVs from CAL62/Rluc cells using electron microscopy, (b) EV size and concentrations were determined by DLS (Avg. 93.1 ± 21.3 nm)., (c) in vivo
imaging of EV-CAL62/Rluc intravenously administered to naïve or CAL62/Effluc tumor-bearing mice, (d) Representative confocal images in EV-CAL62/Rluc/DiD or
EV-CAL62/DiD or EV-CAL62 in CAL62 cells., (e) Representative ex vivo bioluminescent imaging of EV-CAL62/Rluc excised tumor from EV-CAL62/Rluc or PBS
intravenously administered to CAL62/Effluc tumor-bearing mice [83]. Figures adopted and modified from refs [76] and [83] with permission from International
Journal of Nanomedicine and Scientific Reports, respectively.
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very promising and reliable method in the diagnosis and prognosis of
carcinogenesis of human cancers. Recently, Zhu, et al. [100] by de-
termining exosomal tRNAs levels among patients with liver cancer and
healthy individuals, presented that four types of tRNAs including tRNA-
ValTAC-3, tRNA-GlyTCC-5, tRNA-ValAAC-5 and tRNA-GluCTC-5 were
significantly increased in plasma of patients with liver cancer (Fig. 6C).
Therefore, examining their levels as a biomarker provides high hopes
for accurate diagnosis of liver cancer.
5. Major advantages and disadvantages
A lot of drug compounds in the in vivo conditions are very unstable
and have many challenges like a drug resistance, low access to target
tissue and so on for successful treatment. On the other hand, due to the
problems associated with many drug delivery systems such as cyto-
toxicity of organic and non-organic nanoparticles [101], the develop-
ment of delivery systems based on biological patterns is very important.
Because of the minor size of the exosomes between 30–150 nm along
with their hydrophilicity, biocompatibility and cheapness compared to
nanomaterials, this vehicle can progress the constancy of drugs by
loading the drug in the interior space and even on its outer surfaces
through preventing macrophage phagocytosis [102]. Also, exosomes
increase the capability to surrender the nucleic acids like an mRNA or
siRNA to the cytoplasm and even the nucleus of cancer cells by stopping
phagocytosis and preventing lysosomal degradation [103]. Whereas,
exosomes also increase the cellular uptake in drug resistance by cancer
cells. For instance, in a murine model, Kim, et al. [104] exposed that
macrophage-isolated exosomes can transduce Paclitaxel and Taxol into
the lung cells several times more than other carriers such as liposomes.
Moreover, exosomes can reduce the cytotoxicity of drug by decreasing
accumulation of drugs in non-target tissues [14]. However, the lack of a
complete understanding of the nature of exosomes due to their het-
erogeneity resulted from undesirable separation and lack of purity in
production, as well as the possibility of exacerbation of the disease due
to the presence of exosomes that have the same activity as metastatic
cancer exosomes, has been confronted with uncertainties and fear in
clinical practices.
6. Challenges of exosome-based nanocarriers for drug delivery
Despite the high loading efficiency of exosomes, abundance of ori-
ginal materials for them construction, optimal targeting, and scalable
and repeatable manufacturing methods, they could operate as a double-
edged sword in the development and spread of cancerous cells as me-
tastases [105], or the diagnosis of tumor cells for treatment [106],
because the exosomes act naturally as a coded and non-encoded mes-
senger. For example, the immune responses from exosomes in the
treatment of cancers are unclear. Because exosomes are allogeneic
sources and induce immune responses [107]. Moreover, Zhang, et al.
[108] illustrated that EGFR-containing exosomes isolated from gastric
cancer cells can promote the growth of hepatic specific metastasis based
on hepatocyte growth factor activation. Therefore, despite widespread
attention to exosomes, the complexities and ambiguities of the exo-
somes in the treatment of cancers are still not fully understood. In order
to overcome the existing ambiguities, it is necessary to take the ap-
propriate and urgent attention to the following.
Most techniques and approaches for the isolation of cancerous
exosomes are complicated and difficult. However, it is vital that the
complexity of the manufacturing method such as the producing exo-
somes, drug loading, or biomarker binding, must be diminished.
Furthermore, we must pay close attention to the nature of the cancer
cells to produce the exosomes, as well as the type of cargo that is
packed. Because, the high heterogeneity of exosomes even in one type
of cancer is due to the different types of composition on the exosomal
surface. One of the recommended strategies for controlling the loading
of pharmaceutical compounds without destruction of exosomes, rapid
production and reduction of potential immune response activities in
exosomes is the application of cellular engineering techniques.
However, it must be assured that the important structural ingredients of
parental cells, along with the induced compounds on the produced
exosomes, are retained to maintain organotropism.
Besides, the role of exosomes in the diagnosis and treatment of
cancer cells in animal and cell models has been confirmed. However,
large-scale clinical trials need to confirmation and validation the use of
exosome and its associated efficacy in the treatment of cancer cells.
Artificial exosomes or exosomes-inspired liposomes can be used to
prevent possible safety problems associated with exosomes. Autologous
sources can draw more attention in this regard. Furthermore, the
Table 4
Exosomal protein biomarkers in cancer detection.
Tumor Exosomal Protein Stage Detection method Ref.
Exosomal protein
Prostate Survivin Early diagnosis ExoQuick [112]
PCA-3 – PCR analysis [113]
Colorectal CD147, CD9 Metastatic photosensitizer-beads [114]
Lung Annexin, Ras family proteins, CEACAM5 Monitoring Chromatography-mass spectrometry [115]
Glioblastoma EGFR, EGFRvIII, CD63 Monitoring and prediction μNMR system [116]
Melanoma HSP90 Early diagnosis Western blot [117]
Pancreatic Glypican-1 Early diagnosis FACS [118]
Ovarian TGF β1, MAGE 3/6 Prognosis/therapy monitoring Ultracentrifugation [119]
Breast EDIL3 Diagnosis/monitoring ELISA [120]
Fibronectin Early diagnosis ELISA [121]
Gastric GRN – Chromatography-mass spectrometry [122]
Exosomal nucleic acid
Colorectal miRNA-4772-3p Prognosis for recurrent stage II ExoQuick/qPCR [123]
miRNA-1229, miR-150, miRNA-21, Diagnosis Ultracentrifugation/qPCR [124]
Breast miRNA-101, miRNA-372, Diagnosis ExoQuick/qPCR [125]
Prostate miRNA141, miRNA-375 Diagnosis ExoMiR extraction kit /qPCR [126]
PCA3, TMPRSS2-ERG Diagnosis/monitoring qPCR [127]
Glioblastoma Snc RNA (RNU6-1) miRNA-320, Early diagnosis ExoQuick/qPCR [128]
Pancreatic Mutated KRAS DNA Diagnosis/prognosis Ultracentrifugation and Filtration /PCR [94]
bladder GALNT1, LASS2 Diagnosis Microarray [129]
Melanoma miRNA-216a, miRNA217, Metastatic qPCR [130]
Hepatocellular miRNA-718 Tumor size qPCR [131]
Lung miR-17-3p, miRNA-20b Diagnosis/monitoring Microarray [132]
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identification and selection of exosome-based biomarkers in response to
cancer therapies requires further studies and a change in their sa-
tisfaction pattern. Because, the diagnosis and use of drugs by exosomes
containing biomarker could lead to a variety of responses resulting from
the personalization of the experimental or therapeutic process. Other
challenges such as the lack of a precise instruction for the maintenance
of exosomes, the lack of a safe standard with high operation in the
production of exosomes, and even the lack of a proper instruction for
loading multiple drugs in the exosomes, is also observable.
7. Conclusions
Based on the vast variety of activities in the medical field and the
amazing applications of exosomes in it, it is necessary to continually
evaluate the progress made and their challenges. Despite some pro-
gresses in the generation, separation and loading of pharmaceutical
compounds into exosomes, as described in this literature, there are
some serious ambiguities and challenges in using exosomes. The most
important leading challenges include the heterogeneity of exosomal
products, the unclear biological activities of exosomes, the presence of
uncontrollable genomic or protein constituents on their surface that can
induce unwanted activities. However, the function of exosomes in
therapeutic activity is very stimulating and can provide great hope for
controlling the activity of cancer cells. For example, it has been shown
in this review that the using exosomes can improve drug delivery based
on the reduced drug resistance of cancer cells along with enhancing the
imaging quality and prognosis of all types of cancer. On the whole, to
reduce the ambiguity of the use of exosomes in therapeutic activities, it
seems that a wide range of experiments should be performed in cellular,
animal and ultimately human models, so that different immune and
therapeutic responses from these experiments can provide a pattern of
approvable for using exosomes by the medical community.
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Fig. 6. Exosomal biomarker for cancer diagnostic. (A): A set of 10 colon cancer patient samples was assessed by ACE immunoassay for glypican-1 (a) and CD63
(b) levels [90]. (B): (a) Workflow of the ExoSearch chip for continuous mixing, isolation and (b) in-situ, multiplexed detection of circulating exosomes, (c) Bright-field
microscope images of immunomagnetic beads manipulated in microfluidic channel for mixing and isolation of exosomes, (d) Exosome-bound immunomagnetic beads
aggregated in a microchamber with on/off switchable magnet for continuous collection and release of exosomes, and (e) TEM image of exosome-bound im-
munomagnetic bead in a cross-sectional view [88]. (C): Heatmap of differentially expressed tsRNAs between liver cancer patients and healthy donors. N1-N5: five
healthy controls; T1-T5: five liver cancer patients [100]. (D): The expression of microRNA-21 (miR-21) is illustrated in serum exosomes from patients who had
esophageal squamous cell carcinoma (ESCC) and from those who had benign diseases without inflammation [96]. Figures adopted and modified from refs [90], [88]
[100], and [96] with permission from Lab on chips, ACS Nano, Cancer and Molecular cancer, respectively.
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